



Universitat de Lleida

DEGREE CURRICULUM **PHARMACEUTICAL BIOTECHNOLOGY**

Coordination: RIBAS FORTUNY, JUDIT

Academic year 2023-24

Subject's general information

Subject name	PHARMACEUTICAL BIOTECHNOLOGY			
Code	101625			
Semester	1st Q(SEMESTER) CONTINUED EVALUATION			
Typology	Degree	Course	Character	Modality
	Bachelor's Degree in Biotechnology	4	OPTIONAL	Attendance-based
	Master's Degree in Biomedical Research		COMPLEMENTARY TRAINING	Attendance-based
Course number of credits (ECTS)	6			
Type of activity, credits, and groups	Activity type	PRALAB	PRAULA	TEORIA
	Number of credits	0.3	1.4	4.3
	Number of groups	1	1	1
Coordination	RIBAS FORTUNY, JUDIT			
Department	EXPERIMENTAL MEDICINE			
Teaching load distribution between lectures and independent student work	Lectures: 60 hours Independent Student Work: 90 hours			
Important information on data processing	Consult this link for more information.			
Language	Catalan or Spanish			

Teaching staff	E-mail addresses	Credits taught by teacher	Office and hour of attention
RIBAS FORTUNY, JUDIT	judit.ribas@udl.cat	5,8	
RUMI CARRERA, LAURA	lrumi@irbllleida.cat	,2	

Subject's extra information

Pending Translation

Learning objectives

Pending Translation

Competences

Pending Translation

Subject contents

Pending Translation

Methodology

Pending Translation

Development plan

Pending Translation

Evaluation

A first examination will be carried out based on issues and problems of pharmacokinetics and pharmacodynamics. It will generate 28% of the final grade for the subject, therefore it will not be recoverable.

The presentation made about a biotechnological product and the development industry will be evaluated. This presentation generates 22% of the final grade for the subject, therefore it will not be recoverable.

A theoretical exam will be carried out. It will generate 50% of the final grade for the subject, therefore it will be recoverable.

The final pass of the subject is 5, that is, 50%, adding the scores of the 3 aforementioned evaluations. There is no minimum grade in any of the 3 exams that is incompatible with passing the subject.

In all exams and especially in the theoretical one, if the blank answers exceed 50% of all those in the exam, it will imply that the exam is void, that is, the grade NP (Not Presented).

The exams will be objective and multiple choice. Each question will present 4 options of which only one is correct. The blank answer adds 0 points. The error answer subtracts $\frac{1}{4}$ of the value assigned to the question.

A corrective coefficient will be added to the final grade, the calculation of which will be explained on the first day of the course. This coefficient will be applied only to students who pass a score of 6 (60%) in the theoretical exam. At the discretion of the teachers, the coefficient can be modified or stopped applying when aberrant results are generated.

Honor registrations will be awarded to the students with the best grades after obtaining the grades from the first call.

Single evaluation: students who take advantage of this evaluation system will take an objective multi-response test that will contain the entire subject. Each question will present 4 options of which only one is correct. The blank answer adds 0 points. The wrong answer subtracts 25% of the value assigned to the question.

Bibliography

Books:

1. Farmacología. Rang, H.P. et al. (7ª ed.), Elsevier España S.A., 2008
2. Pharmaceutical Biotechnology. Fundamentals and applications. Crommelin D.J.A. et al. (3rd ed), Informa Healthcare USA, Inc., 2008

Journals:

1. Annual Reviews of Pharmacology and Toxicology (<http://arjournals.annualreviews.org/loi/pharmtox>)
2. Trends in Pharmacological Sciences (TIPS), Elsevier
3. Current Opinion in Pharmacology, Elsevier
4. Trends in Biotechnology, Elsevier
5. Current Opinion in Biotechnology, Elsevier

Webs:

1. Agencia Española del Medicamento, Ministerio de sanidad y consumo (<http://www.agemed.es/>)

2. Agencia Europea del Medicamento (<http://www.emea.europa.eu/>)
3. U.S. Food and Drug Administration, Center for Drug Evaluation and Research: (<http://www.fda.gov/cder>)
4. Rx List, the internet drug index (<http://www.rxlist.com/>)